[go: up one dir, main page]

WO2024148178A3 - T cell receptors targeting the highly prevalent kras g12c mutation on hla-a*03:01 in lung cancer - Google Patents

T cell receptors targeting the highly prevalent kras g12c mutation on hla-a*03:01 in lung cancer Download PDF

Info

Publication number
WO2024148178A3
WO2024148178A3 PCT/US2024/010339 US2024010339W WO2024148178A3 WO 2024148178 A3 WO2024148178 A3 WO 2024148178A3 US 2024010339 W US2024010339 W US 2024010339W WO 2024148178 A3 WO2024148178 A3 WO 2024148178A3
Authority
WO
WIPO (PCT)
Prior art keywords
hla
mutation
cell receptors
lung cancer
kras
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/010339
Other languages
French (fr)
Other versions
WO2024148178A2 (en
Inventor
Alexandre REUBEN
Minying ZHANG
John Victor HEYMACH
Gregory A. LIZEE
Peixin JIANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of WO2024148178A2 publication Critical patent/WO2024148178A2/en
Publication of WO2024148178A3 publication Critical patent/WO2024148178A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4253—GTPases, e.g. Ras or Rho

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present disclosure is directed to recombinant T-cell Receptors (TCRs) that binds Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) protein comprising a G12C mutation presented on a human leucocyte antigen-A (HLA-A)*03:01, polynucleotides encoding such TCRs, engineered T-cells comprising such TCRs, and methods of using the same.
PCT/US2024/010339 2023-01-04 2024-01-04 T cell receptors targeting the highly prevalent kras g12c mutation on hla-a*03:01 in lung cancer Ceased WO2024148178A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363478488P 2023-01-04 2023-01-04
US63/478,488 2023-01-04

Publications (2)

Publication Number Publication Date
WO2024148178A2 WO2024148178A2 (en) 2024-07-11
WO2024148178A3 true WO2024148178A3 (en) 2024-08-15

Family

ID=91804270

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/010339 Ceased WO2024148178A2 (en) 2023-01-04 2024-01-04 T cell receptors targeting the highly prevalent kras g12c mutation on hla-a*03:01 in lung cancer

Country Status (1)

Country Link
WO (1) WO2024148178A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018067618A1 (en) * 2016-10-03 2018-04-12 Juno Therapeutics, Inc. Hpv-specific binding molecules
US20190307868A1 (en) * 2016-03-31 2019-10-10 Neon Therapeutics, Inc. Neoantigens and methods of their use
US20210340215A1 (en) * 2018-08-16 2021-11-04 Biontech Us Inc. T cell receptor constructs and uses thereof
WO2022020319A2 (en) * 2020-07-24 2022-01-27 Tscan Therapeutics, Inc. Binding proteins recognizing sars-cov-2 antigens and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190307868A1 (en) * 2016-03-31 2019-10-10 Neon Therapeutics, Inc. Neoantigens and methods of their use
WO2018067618A1 (en) * 2016-10-03 2018-04-12 Juno Therapeutics, Inc. Hpv-specific binding molecules
US20210340215A1 (en) * 2018-08-16 2021-11-04 Biontech Us Inc. T cell receptor constructs and uses thereof
WO2022020319A2 (en) * 2020-07-24 2022-01-27 Tscan Therapeutics, Inc. Binding proteins recognizing sars-cov-2 antigens and uses thereof

Also Published As

Publication number Publication date
WO2024148178A2 (en) 2024-07-11

Similar Documents

Publication Publication Date Title
Denkberg et al. Critical role for CD8 in binding of MHC tetramers to TCR: CD8 antibodies block specific binding of human tumor-specific MHC-peptide tetramers to TCR
Wilde et al. Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity
AU2015259510B2 (en) Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist
US20210355446A1 (en) Artificial hla-positive feeder cell lines for nk cells and uses thereof
CN102272153A (en) High affinity T cell receptor and its application
WO2022081718A8 (en) Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
DePeaux et al. An oncolytic virus–delivered tgfβ Inhibitor overcomes the immunosuppressive tumor microenvironment
EP1320379B8 (en) Use of replication-deficient poxvirus vector to boost cd4+ t cell immune response to antigen
EP1461079B8 (en) Human immunodeficiency virus envelope glycoprotein mutants and uses thereof
WO2024148178A3 (en) T cell receptors targeting the highly prevalent kras g12c mutation on hla-a*03:01 in lung cancer
Anderko et al. Mapping the interplay between NK cells and HIV: therapeutic implications
Ram et al. Adaptive NK cell responses in HIV/SIV infections: a roadmap to cell-based therapeutics?
Michaud et al. Cutting edge: an antibody recognizing ancestral endogenous virus glycoproteins mediates antibody-dependent cellular cytotoxicity on HIV-1–infected cells
WO2024148181A3 (en) T cell receptors targeting the highly prevalent kras g12c mutation on hla-a*11:01 in lung cancer
WO2019109047A1 (en) Binding proteins specific for 5t4 and uses thereof
WO2022140321A3 (en) Mage-b2-specific t-cell receptors
WO2024148183A3 (en) T cell receptors targeting the highly prevalent kras g12v mutation on hla-a*03:01 in lung cancer
WO2024148185A3 (en) T cell receptors targeting the highly prevalent kras g12v mutation on hla-a*11:01 in lung cancer
WO2020221873A8 (en) Car t-cells targeting bcma and uses thereof
Momayyezi et al. Viral escape from NK‐cell‐mediated immunosurveillance: A lesson for cancer immunotherapy?
MX2021002519A (en) Herv-k-derived antigens as shared tumor antigens for anti-cancer vaccine.
Mwimanzi et al. Resistance of major histocompatibility complex class B (MHC-B) to Nef-mediated downregulation relative to that of MHC-A is conserved among primate lentiviruses and influences antiviral T cell responses in HIV-1-infected individuals
MXPA04005832A (en) Peptides for the treatment of cancer associated with the human papilloma virus (hpv) and other epithelial tumours.
Gillespie et al. HLA class I-minor histocompatibility antigen tetramers select cytotoxic T cells with high avidity to the natural ligand
WO2002094860A3 (en) Dimerized t-cell receptor fragment, its compositions and use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24738923

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE